MacroGenics Homepage
10:46 AM | February 04, 2012
Overview
Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn morePartnering
In December 2011, MacroGenics announced an option for a license collaboration with Servier on MGA271.
In October 2010, MacroGenics announced two global partnerships around its DART platform. Learn more
Home»News & Media
News & Media
Recent Press Releases
December 20, 2011 | Press ReleaseMacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim
December 01, 2011 | Press Release
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
June 28, 2011 | Press Release
The Lancet Publishes Data from Protégé, MacroGenics’ Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
> See all Press Releases
Recent News Articles
December 23, 2011 | Gazette.NetMacroGenics, BrainScope Among Bioscience Winners
December 01, 2011 | Bio World
MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M
December 01, 2011 | Fierce Biotech
MacroGenics Pockets $20M in $450 Deal with Servier
> See all News
> Email Alerts: Stay on top of MacroGenics developments.
> Media Kit: Download corporate fact sheet and technology platform overview documents as well as corporate logos.